Executive Summary: Key Legal and Evidentiary Issues

• Disputed treatment of the jointly owned pharmacies as part of the SRX Group, including pooled inventory purchases, unverified manufacturer rebates and questions over inflated inventory invoicing and use of pharmacy credit to support related companies.
• Concerns over related-party dealings and alleged non-disclosure by director Adesh Vora, particularly charitable donation flows and whether they produced any genuine commercial benefit to the pharmacies or instead benefited entities connected to him.
• Serious governance breach alleged in the removal of Sherif Gerges as a director of Woodbine Downs Healthcare Realty Inc., followed by the unilateral sale of its real properties and transfer of approximately $2 million in proceeds to Niam Pharmaceuticals Inc. without his knowledge or consent.
• Procedural contest over whether disputes must be arbitrated under unanimous shareholders’ agreements for the pharmacies, versus being litigated in court through an application for appointment of an inspector and for leave to bring statutory derivative actions.
• Debate over the appropriateness of the extraordinary remedy of appointing an inspector under the OBCA, including whether less expensive means of obtaining financial information existed and whether some issues were potentially statute-barred.
• Challenge to the granting of leave to commence derivative actions, focusing on whether such actions were in the companies’ best interests, whether alternative remedies such as oppression relief were sufficient, and whether limitation period defences should restrict the scope of claims.

Facts of the business relationship and corporate structure

Sherif Gerges and Adesh Vora began their business relationship around 2010 as equal partners in a group of pharmacies. They held direct or indirect equal shareholdings in Seva Drug Mart Inc. and Eglinton Drugs Inc. (together, the “Pharmacies”), which operate retail pharmacies, and in Woodbine Downs Healthcare Realty Inc. (“Woodbine”), a real estate holding company that owned the real estate connected to their operations. Each of them served as a director of Seva, Eglinton and Woodbine.
In June 2011, the Pharmacies and their shareholders entered into unanimous shareholders’ agreements (USAs). These USAs contained dispute-resolution clauses requiring shareholder disputes to be submitted to arbitration under Ontario’s Arbitration Act, 1991. There was no finalized USA for Woodbine, and therefore no arbitration clause directly governing disputes involving that corporation.
On the Vora side of the structure, Mr. Vora also owned or controlled Adesh Vora Pharmacy Professional Corporation, Niam Pharmaceuticals Inc. (“Niam”) and ConnectRx Inc., which sat within a broader SRX Group headed by SRX Health Solutions Inc. (SHSI). SHSI and related companies provided administrative and operational services to the Pharmacies, even though neither Sherif Gerges nor the Pharmacies themselves held shares in SHSI or ConnectRx.

Disputed related-party transactions and financial concerns

The relationship deteriorated when Mr. Gerges raised concerns about how the Pharmacies’ business and finances were being handled within the SRX Group. Inventory purchases for the Pharmacies had been pooled with those of the SRX Group, with manufacturer rebates flowing to SHSI. The independent accountants retained by Mr. Gerges (BDO) could not verify whether all rebates owing to the Pharmacies had been returned, because the information supplied by the appellants was incomplete.
BDO also identified a serious discrepancy between the inventory values reflected on invoices and the inventory actually received by the Pharmacies. Mr. Vora acknowledged that the Pharmacies were being used to buy inventory for other SRX Group pharmacies that were experiencing credit issues. Although this might explain some of the invoicing pattern, BDO was unable to complete a full reconciliation based on the records provided.
Another strand of concern related to a charitable donation arrangement. Seva had agreed to make donations to a hospital foundation but instead paid them to Seva Foundation, a separate entity for which Mr. Vora served as a director. BDO questioned whether Seva obtained any real commercial or economic benefit from this arrangement and whether those donations were in substance benefiting related parties rather than the pharmacy itself. Collectively, these issues were alleged to show a pattern of undisclosed related-party dealings by Mr. Vora in breach of his duties as a director.
Despite two earlier consent court orders requiring production of records (made by Conway J. in May 2024 and Kimmel J. in December 2024), the appellants did not provide sufficient documentation for Mr. Gerges to reconcile the Pharmacies’ related-party transactions or determine their financial impact. The motion judge later found that key records were held by SHSI or other SRX entities controlled by Mr. Vora, beyond the reach of ordinary internal records access.

Unilateral sale of Woodbine’s properties and transfer of proceeds

Tensions escalated further with respect to Woodbine. In April 2024, without Mr. Gerges’ knowledge or consent, Mr. Vora filed an amended corporate profile for Woodbine removing Mr. Gerges as a director. He then caused Woodbine’s real properties to be sold and transferred net proceeds of about $2 million to Niam. These steps were taken without consulting or informing Mr. Gerges, even though both men were equal owners of Woodbine.
In later evidence, Mr. Vora did not deny that Woodbine’s properties were sold and the proceeds transferred in this way. He argued that the pharmacies they jointly owned had been losing substantial amounts, that Mr. Gerges was subject to a non-dissipation order in his family law proceedings (limiting his ability to sell his shares), and that he had arranged inter-company loans and personal advances to keep the businesses afloat. On his account, selling the Woodbine properties was the only viable option to stabilize the group, and he claimed to have various set-off claims against Mr. Gerges that would reduce what was ultimately owed to him as a Woodbine shareholder.

The Superior Court application and interim relief decision

In November 2024, Mr. Gerges, his professional corporation and the jointly owned companies (Seva, Eglinton and Woodbine) brought an application in the Superior Court. They sought:

• An order under Part XIII of the Ontario Business Corporations Act (OBCA) appointing an inspector to investigate the business and financial affairs of the Pharmacies; and
• Leave under s. 246 OBCA to commence derivative actions in the names of the Pharmacies and Woodbine against the Vora-related entities and Mr. Vora personally.
  A draft statement of claim accompanied the application, asserting causes of action including fraud, conversion, constructive trust over the sale proceeds of Woodbine’s properties, unjust enrichment and oppression-type conduct.
  As interim relief, the Gerges side asked for: a Mareva injunction and preservation order over the net proceeds of the Woodbine sale; and production of documents in Mr. Vora’s possession relating to those proceeds. Those motions were heard by Dietrich J. in early February 2025, resulting in a separate decision (the February 2025 Decision). The judge accepted that there was a strong prima facie case at least for conversion of Woodbine’s funds, satisfying the first element of the Mareva test, but held that the remaining elements were not met on the record. The court therefore refused a Mareva injunction and preservation order, and also declined to grant the additional interim production relief, even while recognizing the arguable strength of the conversion claim.

Decision appointing an inspector and granting leave for derivative actions

The remaining parts of the application—appointment of an inspector and leave to commence derivative actions—were argued before Dietrich J. on March 27, 2025. In the decision under appeal (April 2, 2025), the motion judge appointed an inspector to investigate the Pharmacies’ business and financial affairs and granted leave to bring derivative actions on behalf of the Pharmacies and Woodbine.
On the inspector issue, the judge found that the Gerges respondents had met the comparatively low threshold of showing a prima facie case that Mr. Vora had exercised his powers as director in an oppressive or unfairly prejudicial manner. The related-party transactions, BDO’s concerns, and the incomplete compliance with prior production orders together supported the need for an independent investigation. Applying the recognized factors for appointing an inspector (including need for information, availability of alternative and less costly means, risk of tactical advantage, and proportionality of the expense), the judge held that an inspector was appropriate. The prior failure to produce records, and the fact that many key documents were controlled within the SRX Group rather than by the Pharmacies themselves, weighed heavily in favour of this remedy.
Regarding the arbitration clauses in the USAs, the motion judge concluded that they did not bar the court from dealing with the application. The clauses applied only to disputes “between shareholders,” and they expressly excluded the corporations themselves from the definition of “shareholders.” Because the proposed claims were being advanced by the Pharmacies and Woodbine (or in their names) and also involved corporate defendants that were not parties to the USAs, they fell outside the scope of the arbitration agreements. The judge also found that the appellants had participated fully and actively in the court proceedings—accepting service, filing materials, consenting to an order, attending cross-examinations and hearings—without bringing a stay motion under s. 7 of the Arbitration Act. That level of participation amounted to taking steps in the proceeding and attorning to the court’s jurisdiction.
On leave to bring derivative actions, the appellants conceded all but one element of the statutory test, focusing their opposition on whether the proposed actions were in the best interests of the corporations and whether adequate alternative remedies existed (particularly oppression relief). The motion judge concluded that it was in the companies’ best interests to pursue the alleged diversion of corporate funds and related breaches of fiduciary duty. She emphasized that the corporations might have other stakeholders beyond the two equal shareholders, including employees and creditors, and that the evidence did not clearly establish that all of Woodbine’s creditors had been paid. She further held that claims such as conversion and unjust enrichment were corporate claims that could only properly be asserted by the corporations themselves, not personally by Mr. Gerges through an oppression action, and that limitation defences were not sufficiently clear on the existing record to justify cutting back the scope of the investigation or the derivative claims at this early stage.

The Divisional Court appeal: issues and standards

The Vora-related parties appealed to the Divisional Court, arguing that the decision was interlocutory and that leave to appeal was required, and in any event that the motion judge erred in: (1) failing to require the dispute to proceed by arbitration; (2) appointing an inspector; and (3) granting leave for derivative actions.
The Divisional Court first determined that the order below was final rather than interlocutory, following authorities that treat orders granting leave to commence derivative actions or appointing receivers or similar court officers as final for appeal purposes. The usual appellate standards from Housen v. Nikolaisen applied: correctness for questions of law and palpable and overriding error for fact-based or mixed fact-and-law determinations.

Arbitration clauses, competence-competence and court jurisdiction

On the core arbitration point, the court accepted that the first two steps of the Peace River test for a mandatory stay were satisfied: arbitration clauses existed in the Pharmacies’ USAs, and litigation had been commenced. However, it agreed with the motion judge that the remaining two requirements were not met.
First, the proceedings did not fall within the scope of the arbitration agreements. The arbitration clauses were limited to disputes among “shareholders,” expressly excluding the corporations from that category. The Pharmacies themselves were not parties to the arbitration agreements, and there was no USA at all for Woodbine. The fact that the corporate defendants and related entities were controlled by either Gerges or Vora did not transform them into parties to the USAs, and corporate separateness remained fundamental. The Divisional Court held that it was plainly apparent on the face of the record that the Peace River test was not met, so the competence-competence principle did not require the court to defer to an arbitrator on jurisdiction.
Second, the appellants had already taken substantial steps in the court proceedings without invoking the arbitration clauses, including entering a consent order and participating in cross-examinations and hearings. Applying authorities on waiver and attornment, the court endorsed the motion judge’s conclusion that they had effectively given up the right to insist on arbitration.

Inspector appointment and limitation concerns

On the appointment of an inspector, the appellants argued that neutral third parties (such as suppliers or financial institutions) could provide necessary information more cheaply and that an inspector was an extraordinary remedy that should not be used to prepare for litigation or to determine “legitimacy” of spending choices. The Divisional Court rejected this, emphasizing the history of non-compliance with production orders and the fact that the most relevant records were in the possession or control of Vora-related companies, not third parties. In that context, an inspector was both more efficient and more likely to obtain a coherent financial picture than further piecemeal disclosure motions or an audit hampered by missing data.
The court also upheld the motion judge’s treatment of limitation issues. The appellants had argued that claims relating to inventory and invoicing were clearly out of time under the Limitations Act, 2002, dating back at least to a 2022 letter from former counsel. The Divisional Court noted that the judge below had not definitively rejected limitation defences; she had instead found that it was not “clear-cut” on the limited record whether the suspicions in that letter aligned with the eventual pleaded claims, or whether the conduct reflected discrete events or an ongoing pattern. The court held that it was within the motion judge’s discretion to leave limitation questions to be resolved on a fuller evidentiary record rather than artificially limiting the inspector’s mandate at the outset.

Derivative actions, corporate perspective and alternative remedies

On the derivative-action component, the Divisional Court agreed that the remaining contested elements—best interests of the corporations and availability of adequate alternatives—were factual or mixed questions, reviewable only for palpable and overriding error. It endorsed the motion judge’s reasoning that, from a corporate perspective, it is in the Pharmacies’ and Woodbine’s interests to pursue recovery of any funds improperly diverted to Vora-related entities. The fact that Mr. Vora, as a 50 per cent shareholder, might indirectly benefit from any recovery did not undercut the corporations’ interest in being made whole.
The court also accepted that other stakeholders, notably employees and creditors, would be affected by corporate financial health. In addition, it affirmed the conclusion that certain claims—particularly unjust enrichment and conversion of Woodbine’s property—belonged to the corporations alone and could not be pursued solely through a shareholder-level oppression remedy. Authorities on derivative actions, corporate personality and the continued force of the rule in Foss v. Harbottle confirmed that corporate claims must in principle be brought by the corporation, or derivatively in its name, rather than by shareholders seeking to collapse personal and corporate rights.

Outcome and financial orders

Having rejected all grounds of appeal, the Divisional Court dismissed the appeal in full. It upheld the order appointing an inspector to investigate the Pharmacies’ business and financial affairs and the order granting leave to bring derivative actions on behalf of the Pharmacies and Woodbine. The court’s only quantified financial order in this decision was an agreed-upon costs award against the Vora-related appellants in favour of the Gerges respondents. It ordered the appellants to pay all-inclusive costs of CAD $35,000 for the appeal, while the amount of any eventual damages or restitution for the underlying corporate claims remains undetermined and will depend on the outcome of the derivative proceedings.